key: cord-0991238-v1c8up2e
authors: Goyal, Hemant; Sachdeva, Sonali; Perisetti, Abhilash; Mann, Rupinder; Inamdar, Sumant; Tharian, Benjamin
title: Hyperlipasemia and potential pancreatic injury patterns in COVID-19: A marker of severity or innocent bystander?
date: 2020-10-28
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.10.037
sha: fa1687604be20724f9f094467505db3decfb19c4
doc_id: 991238
cord_uid: v1c8up2e

nan

Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome (SARS-CoV-2). Gastrointestinal symptoms are increasingly being reported in COVID-19 1 .

Data on the involvement of the pancreas in COVID-19 has been emerging, and multiple case reports of SARS-CoV-2-induced acute pancreatitis have been published in the literature 2 .

The angiotensin-converting enzyme-2 (ACE-2) is the target receptor of SARS-CoV-2 and is expressed abundantly by both the exocrine and endocrine pancreatic tissues 3 . The presence of ACE-2 in the pancreas could make it susceptible to SARS-CoV-2 resulting in interstitial leakage of pancreatic lipase, adipose tissue lipolysis, and potentially toxic fatty acid-induced damage. These changes can at least contribute to cytokine storm, multiorgan dysfunction, and COVID-19 morbidity 4 . Due to its non-specificity, lipase could be elevated in a myriad of conditions such as infections, renal dysfunction, medication-related, gastrointestinal, and hepatobiliary disease 5 . Given this, it is critical to evaluate the prevalence of hyperlipasemia in COVID-19 and predict clinical outcomes.

We conducted a systematic search using PubMed, Embase, Ovid, and Google Scholar The OpenMeta[Analyst] software was used to estimate the pooled prevalence of lipase elevations among COVID-19 patients and the pooled odds ratio (OR) for severe COVID-19 among this subset of patients. Results were reported with a 95% confidence interval (CI), and a p-value of <0.05 was considered statistically significant. Heterogeneity was assessed using the I 2 test, and I 2 >50% was taken as a measure of moderate inter-study variation.

The initial search yielded 52 articles. After excluding duplicates and reviews articles, seven studies (6 retrospective observational studies and one prospective observational study)

were included in the pooled analysis. A flow chart depicting the study screening and selection process is represented in Supplemental Figure 1 . The results of this pooled analysis are shown in Figure 1 (A & B) . Among 756 COVID-19 patients with available lipase levels, the pooled prevalence of hyperlipasemia was 11.7% (95% CI: 0.094-0.140, P=0.001), and I 2 = 0%. The pooled OR for severe COVID-19 in these patients was 3.143 (95% CI: 1.543-6.400, P=0.003); mild inter-study heterogeneity was observed (I 2 = 27%). Limitations of this study include a modest sample size of 756 COVID-19 patients, of which 92 patients had elevated serum lipase levels. The degree of hyperlipasemia was not uniform across all studies. Potential confounders such as age, comorbidities, and medication use could alter the results of this study. Furthermore, a lack of high-quality randomized controlled trials with adjustment of potential confounders is a notable limitation. Given the inclusion of observational studies, selection bias, information bias, and confounding bias are possible. The prevalence of hyperlipasemia could be underestimated due to a lack of testing and non-reporting of the data in many patients.

Severe pancreatic injury resulting in acute pancreatitis may not be a common event in COVID-19. As evidenced by lipase elevation, mild to moderate pancreatic injury is a clinically significant finding in these patients. Future prospective studies are warranted to ascertain the exact impact of lipase elevation in COVID-19 and guide management strategies for these patients.

J o u r n a l P r e -p r o o f

Taste Changes (Dysgeusia) in COVID-19: A Systematic Review and Meta-analysis

COVID-19 presenting as acute pancreatitis

ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection

Lipotoxicity and cytokine storm in severe acute pancreatitis and COVID-19

Significant elevations of serum lipase not caused by pancreatitis: a systematic review

Pancreatic Injury Patterns in Patients With